William D. Humphries - 19 May 2022 Form 4/A - Amendment Insider Report for PhaseBio Pharmaceuticals Inc

Role
Director
Signature
/s/ John P. Sharp, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
19 May 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
10 Jun 2022, 16:20:34 UTC
Date Of Original Report
20 May 2022
Previous filing
28 Mar 2022
Next filing
06 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Non-employee Director Stock Option (right to buy) Award $0 +11,842 $0.000000 11,842 19 May 2022 Common Stock 11,842 $0.8419 Direct F1, F2
transaction PHASQ Restricted Stock Units Award $0 +2,538 $0.000000 2,538 19 May 2022 Common Stock 2,538 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to correct an error in the total Stock Options and RSUs acquired by the Reporting Person. All other information set forth in the May 20, 2022 Form 4 remains correct.
F2 The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.
F3 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F4 The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.